Opinion Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Med Genet. Jul 20, 2023; 11(3): 28-38
Published online Jul 20, 2023. doi: 10.5496/wjmg.v11.i3.28
Role of IL-2/IL-2 receptor in pathogenesis of autoimmune disorders: Genetic and therapeutic aspects
Sana Rafaqat, Saira Rafaqat
Sana Rafaqat, Department of Biotechnology (Specialized in Human Genetics), Lahore College for Women University, Lahore 54000, Pakistan
Saira Rafaqat, Department of Zoology, Lahore College for Women University, Lahore 54000, Pakistan
Author contributions: All authors contributed equally.
Conflict-of-interest statement: The authors declared no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sana Rafaqat, PhD, Research Fellow, Department of Biotechnology, Lahore College for Women University, G8VG+FR6, Jail Road, Near Wapda Flats, Jubilee Town, Lahore 54000, Pakistan. sana.rafaqat44@gmail.com
Received: April 13, 2023
Peer-review started: April 13, 2023
First decision: June 1, 2023
Revised: June 10, 2023
Accepted: June 30, 2023
Article in press: June 30, 2023
Published online: July 20, 2023
Core Tip

Core Tip: Immune dysregulation of Interleukin-2 (IL-2) may cause tissue injury and damage leads to pathogenesis of various autoimmune diseases The aim of this review paper was to examine the role of IL-2/IL-2R in various autoimmune disorders, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS) and Sjogren Syndrome (SS), which are all linked to malfunctioning of IL-2/IL-2R. IL-2 gene polymorphism is involved in increasing the risk of SLE, RA, SSc, and MS but no data has been available about the genetic role of IL-2 in the pathogenesis of Sjogren syndrome. In therapeutic approaches, a low dose of IL-2 therapy is found to be safe, effective, and well-tolerated in the treatment of SLE, RA, SSc, MS, and SS patients.